Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is a pharmaceutical specialty company. The company focuses on anti-infective drugs in adjuvant cancer care, prescription medications, and mesenchymal stem cell therapy while developing and commercializing vital treatment benefits. Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite, and I/ONTAK are the company's five products.

Key Highlights

• I/ONTAK (E7777) completed its pivotal Phase 3 study in December 2021, with topline data expected in the first half of 2022, a biologics licensing application (BLA) filing in the second part of 2022, and the completion of the Mino-Lok Phase 3 trial in 2022.
• The first quarter of 2021 concluded with a net loss of USD 9.2 million, or (USD 0.06) per share, compared to a net loss of USD 8.1 million, or (USD 0.15) per share, in the first quarter of 2020. A rise in general and administrative expenditures is largely responsible for the increase in a net loss.
• For the first quarter ended December 31, 2021, R&D costs were USD 5.5 million, compared to USD 6.2 million for the first quarter ended December 31, 2020, while G&A expenses were USD 2.9 million, compared to USD 1.7 million for the first quarter ended December 31, 2020. The USD 1.2 million increase is mostly attributable to extra pay expenditures for new staff as well as performance bonuses.
• The Company estimates that its available financial resources will be adequate to sustain its operations through March 2023, with cash and cash equivalents of USD 65.4 million as of December 31, 2021.
• Stock-based compensation expenditure was USD 0.9 million in the fiscal quarter ended December 31, 2021, compared to USD 0.3 million the previous year. The rise is mostly due to costs associated with new Citius grants to workers, directors, and consultants.
• CTXR stock is in a downtrend from the previous year June after making a high of USD 4.56 and since then corrected almost 80.68% since then. The current price is below both short-term (50-day) SMA and long-term (200-day) SMA. A break above the price of USD 1.00, might bring some bullish momentum into the stock and till then bears are expected to be in power comparatively.

One-year technical Price Chart (as of 13 May 2022). Source: REFINITIV, Analysis by Kalkine Group

Stock Recommendation

CTXR's stock price has fallen 51.08% in the past six months and is currently leaning toward the lower end of its 52-week range of USD 0.86 to USD 4.56. 

Given the stock's considerable bearish price movement over the past six months, financial results, and technical analysis, we propose a "Watch" rating on the stock at its closing price of USD 0.90, as of 13 May 2022.

Technical Analysis Summary

* Closing price as of 13 May 2022.

Investors can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario.

Technical Indicators Defined: -

Support: A level where-in the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest.

Resistance: A level where-in the stock prices tend to find resistance when they are rising, and the uptrend may take a pause due to profit booking or selling interest.

Stop-loss: It is a level to protect further losses in case of unfavorable movement in the stock prices.

Note 1: The reference data in this report has been partly sourced from REFINITIV.  

Note 2: Investment decisions should be made depending on the investors' appetite for upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting the stock if the Target Price mentioned as per the valuation has been achieved and subject to the factors discussed above. 

Note 3: The report publishing date is as per the Pacific Time Zone.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.